Ignite Creation Date:
2024-05-05 @ 12:06 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00245947
Status:
COMPLETED
Last Update Posted:
2009-09-10
First Post:
2005-10-26
Brief Title:
Study Evaluating ERB-041 in Active Crohns Disease
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Multicenter Randomized Double-Blind Placebo-Controlled Parallel- Design Exploratory Pharmacogenomic Safety and Activity Study of Orally Administered ERB-041 in Subjects With Inflammation Associated With Active Crohns Disease
Status:
COMPLETED
Status Verified Date:
2009-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohns disease
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None